<DOC>
	<DOCNO>NCT02103335</DOCNO>
	<brief_summary>This Phase 1 clinical trial evaluate new combination drug treatment relapse refractory ( drug-resistant ) multiple myeloma . The drug study : - Pomalidomide ( POMALYST® ) drug affect immune system ( immunomodulatory drug ) approve United States ( US ) Food Drug Administration ( FDA ) treatment multiple myeloma . - Marizomib investigational drug develop Triphase study treatment multiple myeloma . Investigational drug drug yet approve health authority , FDA , general use approve use specific clinical study . Marizomib inhibit cellular machine call proteasome , destroy unnecessary damage protein . Other proteasome inhibitor show effective treatment multiple myeloma . - Dexamethasone corticosteroid drug affect immune system ( immunomodulatory drug ) approve FDA treatment multiple myeloma . This first study evaluate three-drug combination pomalidomide ( POM ) , marizomib ( MRZ ) , dexamethasone ( LD-DEX ) human . Pomalidomide , alone combination dexamethasone , approve FDA treatment relapse refractory multiple myeloma . The primary objective study determine best drug dosing level three-drug combination , include high safe dos and/or recommend dos future clinical study drug combination . The secondary purpose study determine safety drug combination effectiveness treat relapse refractory multiple myeloma . The study include examination level three drug blood various time point treatment .</brief_summary>
	<brief_title>Combination Study Pomalidomide , Marizomib , Low-Dose Dexamethasone Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Inclusion Criteria Subjects must meet follow criterion eligible study participation : 1 . At least 18 year time signing informed consent form . 2 . Able understand voluntarily sign informed consent form prior studyrelated assessments/procedures . 3 . Able adhere study visit schedule protocol requirement . 4 . Documented diagnosis multiple myeloma measurable disease serum urine protein electrophoresis ( SPEP UPEP ) : SPEP ≥0.5 g/dL , UPEP ≥200 mg/24 hour , involve serum free light chain ( FLC ) level ≥10 mg/dL provide serum FLC ratio abnormal . 5 . Previously receive 1 line antimyeloma therapy must include lenalidomide bortezomib ( either separately combination ) . 6 . Documented disease progression within 60 day recent line anti myeloma therapy . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status score ≤2 . 8 . All study participant USA must register mandatory POMALYST REMS™ ( Risk Evaluation &amp; Mitigation Strategy ) program , willing able comply requirement POMALYST REMS™ program . 9 . All study participant USA female childbearing potential ( FCBP ) must adhere schedule pregnancy test require POMALYST REMS™ program . 10 . All study participant outside USA must agree comply POMALYST® PPRMP requirement . 11 . All subject must able agree take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( patient intolerant ASA may use warfarin low molecular weight heparin ) . 12 . For female child bear potential ( FCBP ) : Agree use 2 reliable form contraception simultaneously practice complete abstinence heterosexual contact least 28 day start study treatment , participate study ( include dose interruption ) , least 28 day study treatment discontinuation ; must follow pregnancy test requirement outline POMALYST REMS™ program PPRMP . 13 . For female : Agree abstain breastfeed study participation least 28 day study treatment discontinuation . 14 . For male : Agree use latex synthetic condom sexual contact FCBP participate study least 28 day follow discontinuation study treatment , even undergone successful vasectomy . 15 . For male : Agree refrain donate semen sperm study least 28 day discontinuation study treatment . 16 . Refrain donate blood study treatment least 28 day discontinuation study treatment . 17 . Agree share medication . Exclusion Criteria Subjects follow exclude participation study : 1 . Peripheral neuropathy Grade ≥2 . 2 . Nonsecretory multiple myeloma . 3 . Any following laboratory abnormality : ANC &lt; 1,000/µL ; Platelet count &lt; 50,000/µL subject &lt; 50 % bone marrow nucleate cell plasma cell ; platelet count &lt; 30,000/µL subject ≥50 % bone marrow nucleate cell plasma cell ; Creatinine clearance ( CrCL ) &lt; 45 mL/min measure directly calculate accord Cockcroft Gault formula ; Corrected serum calcium &gt; 13.5 mg/dL ( &gt; 3.4 mmol/L ) ; Hemoglobin &lt; 8 g/dL ( &lt; 4.9 mmol/L ; prior red blood cell [ RBC ] transfusion recombinant human erythropoietin use permit study entry ) ; Serum aspartate aminotransferase ( AST ) &gt; 3.0 x upper limit normal ( ULN ) ; Serum alanine aminotransferase ( ALT ) &gt; 3.0 x ULN ; Serum total bilirubin &gt; 1.5 x ULN ( &gt; 3.0 x ULN subject know Gilbert 's disease ) . 4 . Prior history malignancy , MM , unless subject free disease ≥5 year . Subjects may enter early 5 year receive curative treatment follow : Basal cell carcinoma skin ; Squamous cell carcinoma skin ; Carcinoma situ cervix ; Carcinoma situ breast ; Or : Incidental histologic find prostate cancer ( T1a T1b use TNM [ tumor , node , metastasis ] clinical staging system ) non metastatic prostate cancer complete remission require treatment . 5 . Previous therapy POM and/or MRZ . 6 . History allergic reaction hypersensitivity thalidomide , lenalidomide , bortezomib , carfilzomib , boron , mannitol , DEX . 7 . Grade ≥3 rash prior thalidomide lenalidomide therapy . 8 . Gastrointestinal disease may significantly alter absorption POM . 9 . History follow : Congestive heart failure Class III IV New York Heart Association ( NYHA ) classification ; Myocardial infarction within 12 month prior start study treatment ; Unstable poorly control angina pectoris , include Prinzmetal variant angina pectoris . 10 . Any follow within 14 day prior initiation study treatment : Plasmapheresis ; Major surgery ( kyphoplasty consider major surgery ) ; Radiation therapy ; Antimyeloma drug therapy . 11 . Received investigational agent within 28 day 5 halflives ( whichever longer ) prior initiation study treatment . 12 . Conditions require chronic steroid immunosuppressive treatment ( eg , rheumatoid arthritis , multiple sclerosis , lupus ) , likely need additional steroid immunosuppressive treatment addition study treatment . 13 . Subjects may receive corticosteroid ( &gt; 10 mg/day prednisone equivalent ) within 3 week prior enrollment ( use steroidal inhalation aerosol asthma permit ) . 14 . Unable unwilling undergo antithrombotic prophylactic treatment . 15 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study , determine Investigator . 16 . Pregnant and/or breastfeeding female . 17 . Known seropositive active viral infection human immunodeficiency virus ( HIV ) . 18 . Known seropositive active viral infection hepatitis B virus ( HBV ) , follow exception : negative eligible . Subjects hepatitis B receive antiviral treatment show nondetectable viral DNA 6 month eligible . Subjects seropositive hepatitis B virus vaccine eligible . 19 . Known seropositive active viral infection hepatitis C virus ( HCV ) , follow exception : Subjects hepatitis C receive antiviral treatment show detectable viral ribonucleic acid ( RNA ) 6 month eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Pomalidomide</keyword>
	<keyword>Marizomib</keyword>
	<keyword>Low dose Dexamethasone</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>